^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | PLD-102 (RET inhibitor, FLT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Discovery of PLM-102, a highly potent 3rd generation FLT3 inhibitor, in drug-resistant FLT3-ITD-TKD mutated acute myeloid leukemia
Published date:
03/15/2023
Excerpt:
Moreover, in AML-related xenograft mouse models (MV4-11, MOLM-14, Ba/F3-ITD-D835Y, Ba/F3-ITD-F691L), once-daily oral dose of PLM-102 significantly suppressed the tumor growth and achieved complete tumor regression. In addition, the outstanding efficacy of our compound has been confirmed in large tumor xenograft models...In conclusion, PLM-102 is a promising therapeutic candidate for the FLT3-ITD-mutated AML...
